12:00 AM
 | 
Nov 18, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Kadcyla trastuzumab emtansine regulatory update

Chugai said it postponed the price listing of Kadcyla trastuzumab emtansine on Japan's National Health Insurance (NHI) reimbursement list after the company and Japan's Ministry of Health, Labor and Welfare (MHLW) could not agree on the "medical value" of the breast cancer drug. The pharma...

Read the full 204 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >